Alkermes Drug for Depression Gets a Second Chance from the FDA
- Posted by ISPE Boston
- On May 2, 2018
Alkermes has announced that the FDA has accepted for review its New Drug Application (NDA) for ALKS 5461, a drug for the treatment of major depressive disorder (MDD) in patients who meet certain criteria. FDA’s acceptance of the NDA came just two weeks after the agency issued a Refusal to File letter and follows discussions […]
Read More